Paclitaxel (Taxol)

New England Journal of Medicine

Volumn 332, Issue 15, 1995, Pages 1004-1014

  Wood, Alastair J J ^a   Rowinsky, Eric K ^a   Donehower, Ross C ^b  

^a Pharmacology and Experimental Therapeutics   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PACLITAXEL; DOCETAXEL;

BREAST TUMOR; DRUG HYPERSENSITIVITY; FEMALE; HEART ARRHYTHMIA; HUMAN; IATROGENIC DISEASE; OVARY TUMOR; PERIPHERAL NEUROPATHY; REVIEW; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; BINDING AFFINITY; BLOOD TOXICITY; BREAST CANCER; CANCER THERAPY; CARDIOTOXICITY; CLINICAL TRIAL; DRUG BINDING; HEAD AND NECK CANCER; HYPERSENSITIVITY REACTION; LUNG CANCER; NEUROTOXICITY; OVARY CANCER; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL;

ARRHYTHMIA; BREAST NEOPLASMS; DRUG HYPERSENSITIVITY; FEMALE; HUMAN; OVARIAN NEOPLASMS; PACLITAXEL; PERIPHERAL NERVOUS SYSTEM DISEASES;

EID: 84994521433     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM199504133321507     Document Type: Review

References (119)

1. Wani MC, Taylor HL, Wall ME, Coggan P, McPhail AT Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 1971; 93.: 2325-2327
2. Schiff PB, Fant J, Horwitz SB Promotion of microtubule assembly in vitro by taxol. Nature 1979; 277.: 665-667
3. Schiff PB, Horwitz SB Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci U S A 1980; 77.: 1561-1565
4. Rowinsky EK, Cazenave LA, Donehower RC Taxol.: a novel investigational antimicrotubule agent. J Natl Cancer Inst 1990; 82.: 1247-1259
5. Dustin P Microtubules. Sci Am 1980; 243.: 66-76
6. Wilson L Microtubules as drug receptors.: pharmacological properties of microtubule protein. Ann N Y Acad Sci 1975; 253.: 213-231
7. Crossin KL, Carney DH Microtubule stabilization to taxol inhibits initiation of DNA synthesis by thrombin and by epidermal growth factor. Cell 1981; 27.: 341-350
8. Parness J, Horwitz SB Taxol binds to polymerized tubulin in vitro. J Cell Biol 1981; 91.: 479-487
9. Manfredi JJ, Parness J, Horwitz SB Taxol binds to cellular microtubules. J Cell Biol 1982; 94.: 688-696
10. Schiff PB, Horwitz SB Taxol assembles tubulin in the absence of exogenous guanosine 5'-triphosphate or microtubule-associated proteins. Biochemistry 1981; 20.: 3247-3252
11. Kumar N Taxol-induced polymerization of purified tubulin.: mechanism of action. J Biol Chem 1981; 256.: 10435-10441
12. Wilson L, Miller HP, Farrell KW, Snyder KB, Thompson WC, Purich DL Taxol stabilization of microtubules in vitro.: dynamics of tubulin addition and loss at opposite microtubule ends. Biochemistry 1985; 24.: 5254-5262
13. Hamel E, del Campo AA, Lowe MC, Lin C Interactions of taxol, microtubule-associated proteins, and guanine nucleotides in tubulin polymerization. J Biol Chem 1981; 256.: 11887-11894
14. Jordan MA, Toso RJ, Thrower D, Wilson L Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc Natl Acad Sci U S A 1993; 90.: 9552-9556
15. Burkhart CA, Berman JW, Swindell CS, Horwitz SB Relationship between the structure of taxol and other taxanes on induction of tumor necrosis factor-α gene expression and cytotoxicity. Cancer Res 1994; 54.: 5779-5782
16. Rao S, Horwitz SB, Ringel I Direct photoaffinity labeling of tubulin with taxol. J Natl Cancer Inst 1992; 84.: 785-788
17. Rao S, Krauss NE, Heerding JM, 3'-(p-Azidobenzamido)taxol photolabels the N-terminal 31 amino acids of beta-tubulin. J Biol Chem 1994; 269.: 3132-3134
18. Rowinsky EK, Donehower RC, Jones RJ, Tucker RW Microtubule changes and cytotoxicity in leukemic cell lines treated with taxol. Cancer Res 1988; 48.: 4093-4100
19. Roberts JR, Allison DC, Donehower RC, Rowinsky EK Development of polyploidization in taxol-resistant human leukemia cells in vitro. Cancer Res 1990; 50.: 710-716
20. Rowinsky EK, Burke PJ, Karp JE, Tucker RW, Ettinger DS, Donehower RC Phase I and pharmacodynamic study of taxol in refractory adult acute leukemias. Cancer Res 1989; 49.: 4640-4647
21. De Brabander M, Geuens G, Nuydens R, Willebrords R, De Mey J Taxol induces the assembly of free microtubules in living cells and blocks the organizing capacity of the centrosomes and kinetochores. Proc Natl Acad Sci U S A 1981; 78.: 5608-5612
22. Tishler RB, Schiff PB, Geard CR, Hall EJ Taxol.: a novel radiation sensitizer. Int J Radiat Oncol Biol Phys 1992; 22.: 613-617
23. Tishler RB, Geard CR, Hall EJ, Schiff PB Taxol sensitizes human astrocytoma cells to radiation. Cancer Res 1992; 52.: 3495-3497
24. Choy H, Akerley W, Safran H, Phase I trial of outpatient weekly paclitaxel and concurrent radiation therapy for advanced non-small-cell lung cancer. J Clin Oncol 1994; 12.: 2682-2686
25. Cabral F, Wible L, Brenner S, Brinkley BR Taxol-requiring mutant of Chinese hamster ovary cells with impaired mitotic spindle assembly. J Cell Biol 1983; 97.: 30-39
26. Horwitz SB, Cohen D, Rao S, Ringel I, Shen HJ, Yang CP Taxol.: mechanisms of action and resistance. Monogr Natl Cancer Inst 1993; 15.: 55-61
27. Gupta RS Taxol resistant mutants of Chinese hamster ovary cells.: genetic biochemical, and cross-resistance studies. J Cell Physiol 1983; 114.: 137-144
28. Legha SS, Tenney DM, Krakoff IR Phase I study of taxol using a 5-day intermittent schedule. J Clin Oncol 1986; 4.: 762-766
29. Grem JL, Tutsch KD, Simon KJ, Phase I study of taxol administered as a short i.v. infusion daily for 5 days. Cancer Treat Rep 1987; 71.: 1179-1184
30. Kris MG, O'Connell JP, Gralla RJ, Phase I trial of taxol given as a 3-hour infusion every 21 days. Cancer Treat Rep 1986; 70.: 605-607
31. Schiller JH, Storer B, Tutsch K, Phase I trial of 3-hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer. J Clin Oncol 1994; 12.: 241-248
32. Donehower RC, Rowinsky EK, Grochow LB, Longnecker SM, Ettinger DS Phase I trial of taxol in patients with advanced cancer. Cancer Treat Rep 1987; 71.: 1171-1177
33. Brown T, Havlin K, Weiss G, A phase I trial of taxol given by a 6-hour intravenous infusion. J Clin Oncol 1991; 9.: 1261-1267
34. Wiernik PH, Schwartz EL, Strauman JJ, Dutcher JP, Lipton RB, Paietta E Phase I clinical and pharmacokinetic study of taxol. Cancer Res 1987; 47.: 2486-2493
35. Wiernik PH, Schwartz EL, Einzig A, Strauman JJ, Lipton RB, Dutcher JP Phase I trial of taxol given as a 24-hour infusion every 21 days.: responses observed in metastatic melanoma. J Clin Oncol 1987; 5.: 1232-1239
36. Ohnuma T, Zimet AS, Coffey VA, Holland JF, Greenspan EM Phase I study of taxol in a 24-hour infusion schedule. Proc Am Assoc Cancer Res 1985; 26.: 167-167 abstract.
37. Hurwitz CA, Relling MV, Weitman SD, Phase I trial of paclitaxel in children with refractory solid tumors.: a Pediatric Oncology Group study. J Clin Oncol 1993; 11.: 2324-2329
38. Sarosy G, Kohn E, Stone DA, Phase I study of taxol and granulocyte colony-stimulating factor in patients with refractory ovarian cancer. J Clin Oncol 1992; 10.: 1165-1170
39. Wilson WH, Berg S, Bryant G, Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer.: a phase I/II trial of 96-hour infusion. J Clin Oncol 1994; 12.: 1621-1629
40. Spriggs DR, Tondini C Taxol administered as a 120 hour infusion. Invest New Drugs 1992; 10.: 275-278
41. Rowinsky EK, Eisenhauer EA, Chaudhry V, Arbuck SA, Donehower RC Clinical toxicities encountered with paclitaxel (Taxol). Semin Oncol 1993; 20.: Suppl 3.: 1-15
42. Adams JD, Flora KP, Goldspiel BR, Wilson JW, Arbuck SG, Finley A Taxol.: a history of pharmaceutical development and current pharmaceutical concerns. Monogr Natl Cancer Inst 1993; 15.: 141-147
43. Lasser EC, Walters A, Reuter SR, Lang J Histamine release by contrast media. Radiology 1971; 100.: 683-686
44. Weiss RB, Donehower RC, Wiernik PH, Hypersensitivity reactions from taxol. J Clin Oncol 1990; 8.: 1263-1268
45. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer.: high-dose versus low-dose and long versus short infusion. J Clin Oncol 1994; 12.: 2654-2666
46. Lorenz W, Reimann HJ, Schmal A, Histamine release in dogs by Cremophor E1 and its derivatives.: oxethylated oleic acid is the most effective constituent. Agents Actions 1977; 7.: 63-67
47. Lassus M, Scott D, Leyland-Jones B Allergic reactions associated with cremophor containing antineoplastics. Proc Am Soc Clin Oncol 1985; 4.: 268-268 abstract.
48. Peereboom D, Donehower RC, Eisenhauer EA, Successful re-treatment with taxol after major hypersensitivity reactions. J Clin Oncol 1993; 11.: 885-890
49. Laskin MS, Lucchesi KJ, Morgan M Paclitaxel rechallenge failure after a major hypersensitivity reaction. J Clin Oncol 1993; 11.: 2456-2457
50. McGuire WP, Rowinsky EK, Rosenshein NB, Taxol.: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 1989; 111.: 273-279
51. Holmes FA, Walters RS, Theriault RL, Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 1991; 83.: 1797-1805
52. Huizing MT, Keung ACF, Rosing H, Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients. J Clin Oncol 1993; 11.: 2127-2135
53. Rowinsky EK, Chaudhry V, Cornblath DR, Donehower RC Neurotoxicity of taxol. Monogr Natl Cancer Inst 1993; 15.: 107-115
54. Thigpen JT, Blessing JA, Ball H, Hummel SJ, Barrett RJ Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy.: a Gynecological Oncology Group study. J Clin Oncol 1994; 12.: 1748-1753
55. Trimble EL, Adams JD, Vena D, Paclitaxel for platinum-refractory ovarian cancer.: results from the first 1,000 patients registered to National Cancer Treatment Referral Center 9103. J Clin Oncol 1993; 11.: 2405-2410
56. Chaudhry V, Rowinsky EK, Sartorius SE, Donehower RC, Cornblath DR Peripheral neuropathy from taxol and cisplatin combination chemotherapy.: clinical and electrophysiological studies. Ann Neurol 1994; 35.: 304-311
57. Capri G, Munzone E, Tarenzi E, Optic nerve disturbances.: a new form of paclitaxel neurotoxicity. J Natl Cancer Inst 1994; 86.: 1099-1101
58. Rowinsky EK, Chaudhry V, Forastiere AA, Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor.: neuromuscular toxicity is dose-limiting. J Clin Oncol 1993; 11.: 2010-2020
59. Rowinsky EK, Gilbert M, McGuire WP, Sequences of taxol and cisplatin.: a phase I and pharmacologic study. J Clin Oncol 1991; 9.: 1692-1703
60. Rowinsky EK, McGuire WP, Guarnieri T, Fisherman JS, Christian MC, Donehower RC Cardiac disturbances during the administration of taxol. J Clin Oncol 1991; 9.: 1704-1712
61. Arbuck SG, Strauss H, Rowinsky E, A reassessment of the cardiac toxicity associated with Taxol. Monogr Natl Cancer Inst 1993; 15.: 117-130
62. Gianni L, Straneo G, Capri F, Optimal dose and sequence finding study of paclitaxel (P) by 3 h infusion with bolus doxorubicin (D) in untreated metastatic breast cancer patients (Pts). Proc Am Soc Clin Oncol 1994; 13.: 74-74 abstract.
63. Pestalozzi BC, Sotos GA, Choyke PL, Fisherman JS, Cowan KH, O'Shaughnessy JA Typhlitis resulting from treatment with taxol and doxorubicin in patients with metastatic breast cancer. Cancer 1993; 71.: 1797-1800
64. Kennedy MJ, Armstrong D, Donehower R, The hematologic toxicity of the taxol/cytoxan doublet is sequence-dependent. Proc Am Soc Clin Oncol 1994; 13.: 137-137 abstract.
65. Ajani JA, Dodd LG, Daugherty K, Warkentin D, Ilson DH Taxol-induced soft-tissue injury secondary to extravasation.: characterization by histopathology and clinical course. J Natl Cancer Inst 1994; 86.: 51-53
66. Shenkier T, Gelmon K Paclitaxel and radiation-recall dermatitis. J Clin Oncol 1994; 12.: 439-439
67. Longnecker SM, Donehower RC, Cates AE, High-performance liquid chromatographic assay for taxol in human plasma and urine and pharmacokinetics in a phase I trial. Cancer Treat Rep 1987; 71.: 53-59 [Erratum, Cancer Treat Rep 1987;71.:340.]
68. Sonnichsen DS, Hurwitz CA, Pratt CB, Shuster JJ, Relling MV Saturable pharmacokinetics and paclitaxel pharmacodynamics in children with solid tumors. J Clin Oncol 1994; 12.: 532-538
69. Rowinsky EK, Donehower RC The clinical pharmacology of paclitaxel. Semin Oncol 1993; 20.: Suppl 3.: 16-25
70. Gianni L, Kearns C, Gianni A, Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol 1995; 13.: 180-190
71. Schilder LE, Egorin MJ, Zuhowski EG, Rossof AH The pharmacokinetics of taxol in a dialysis patient. Proc Am Soc Clin Oncol 1994; 13.: 136-136 abstract.
72. Monsarrat B, Mariel E, Cros S, Taxol metabolism.: isolation and identification of three major metabolites in rat bile. Drug Metab Dispos Biol Fate Chem 1990; 18.: 895-901
73. Monsarrat B, Alvinerie P, Wright M, Hepatic metabolism and biliary excretion of Taxol in rats and humans. Monogr Natl Cancer Inst 1993; 15.: 39-46
74. Cresteil T, Monsarrat B, Alvinerie P, Treluyer JM, Vieira I, Wright M Taxol metabolism by human liver microsomes.: identification of cytochrome P450 isozymes involved in its biotransformation. Cancer Res 1994; 54.: 386-392
75. Harris JW, Rahman A, Kim BR, Guengerich P, Collins JM Metabolism of taxol by human hepatic microsomes and liver slices.: participation of cytochrome P450 3A4 and an unknown P450 enzyme. Cancer Res 1994; 15.: 4026-4035
76. Venook AP, Egorin M, Brown TD, Paclitaxel (Taxol) in patients with liver dysfunction (CALGB 9264). Proc Am Soc Clin Oncol 1994; 13.: 139-139 abstract.
77. LeBlanc GA, Sundseth SS, Weber GF, Waxman DJ Platinum anticancer drugs modulate P-450 mRNA levels and differentially alter hepatic drug and steroid hormone metabolism in male and female rats. Cancer Res 1992; 52.: 540-547
78. Rowinsky EK, Citardi M, Noe DA, Donehower RC Sequence-dependent cytotoxic effects due to combinations of cisplatin and the antimicrotubule agents taxol and vincristine. J Cancer Res Clin Oncol 1993; 119.: 727-733
79. McGuire WP, Hoskins WJ, Brady MR, A phase III trial comparing cisplatin/cytoxan (pc) and cisplatin/taxol (pc) in advanced ovarian cancer (aoc). Proc Am Soc Clin Oncol 1993; 12.: 255-255 abstract.
80. Holmes FA, Newman RA, Madden T, Schedule dependent pharmacokinetics (PK) in a phase I trial of taxol (T) and doxorubicin (D) as initial chemotherapy for metastatic breast cancer. Ann Oncol 1994; 5.: Suppl 5.: 197-197 abstract.
81. Einzig AI, Wiernik PH, Sasloff J, Runowicz CD, Goldberg GL Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma. J Clin Oncol 1992; 10.: 1748-1753
82. Kohn EC, Sarosy G, Bicher A, Dose-intense taxol.: high response rate in patients with platinum-resistant recurrent ovarian cancer. J Natl Cancer Inst 1994; 86.: 18-24
83. Stanhope CR, Smith JP, Rutledge F Second trial drugs in ovarian cancer. Gynecol Oncol 1977; 5.: 52-58
84. Wiltshaw E, Subramarian S, Alexopoulos C, Barker GH Cancer of the ovary.: a summary of experience with cis-dichlorodiammineplatinum(II) at the Royal Marsden Hospital. Cancer Treat Rep 1979; 63.: 1545-1548
85. McGuire WP. Paclitaxel in the treatment of ovarian cancer. In.: Proceedings of the 30th Annual Meeting of the American Society of Clinical Oncology, Dallas, May 14-17, 1994. American Society of Clinical Oncology Educational Book. Chicago.: American Society of Clinical Oncology, 1994.:204-13.
86. Reichman BS, Seidman AD, Crown JP, Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer. J Clin Oncol 1993; 11.: 1943-1951
87. Seidman A, Crown J, Reichman B, Lack of cross-resistance of taxol (T) with anthracycline (A) in the treatment of metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 1993; 12.: 63-63 abstract.
88. Gelmon K, Nabholtz JM, Bontenbal M, Randomized trial of two doses of paclitaxel in metastatic breast cancer after failure of standard therapy. Ann Oncol 1994; 5.: Suppl 5.: 198-198 abstract.
89. Holmes FA, Valero V, Theriault RL, Phase II trial of taxol (T) in metastatic breast cancer (MBC) refractory to multiple prior treatments. Proc Am Soc Clin Oncol 1993; 12.: 94-94 abstract.
90. Hudis C, Seidman A, Baselga J, Sequential high dose adjuvant doxorubicin (A), paclitaxel (T), and cyclophosphamide (C) with G-CSF is feasible for women (pts) with resected breast cancer (BC) and >4 (+) lymph nodes (LN). Proc Am Soc Clin Oncol 1994; 13.: 65-65 abstract.
91. Murphy WK, Fossella FV, Winn RJ, Phase II study of taxol in patients with untreated non-small-cell lung cancer. J Natl Cancer Inst 1993; 85.: 384-388
92. Chang AY, Kim K, Glick J, Anderson T, Karp D, Johnson D Phase II study of taxol, merbarone, and piroxantrone in stage IV non-small-cell lung cancer.: the Eastern Cooperative Oncology Group results. J Natl Cancer Inst 1993; 85.: 388-394
93. Ettinger DS, Finkelstein DM, Sarma R, Johnson DH Phase II study of taxol in patients with extensive-stage small cell lung cancer. Proc Am Soc Clin Oncol 1993; 12.: 329-329 abstract.
94. Kirschling RJ, Jung SH, Jett JR A phase II trial of taxol and GCSF in previously untreated patients with extensive stage small cell lung cancer. Proc Am Soc Clin Oncol 1994; 13.: 326-326 abstract.
95. Forastiere AA, Neuberg D, Taylor SG, Deconti R, Adams G Phase II evaluation of Taxol in advanced head and neck cancer.: an Eastern Cooperative Oncology Group trial. Monogr Natl Cancer Inst 1993; 15.: 181-184
96. Einzig AI, Hochster H, Wiernik PH, A phase II study of taxol in patients with malignant melanoma. Invest New Drugs 1991; 9.: 54-64
97. Legha SS, Ring S, Papadopoulos N, Raber M, Benjamin RS A phase II trial of taxol in metastatic melanoma. Cancer 1990; 65.: 2478-2481
98. Einzig AI, Gorowski E, Sasloff J, Wiernik PH Phase II trial of taxol in patients with metastatic renal cell carcinoma. Cancer Invest 1991; 9.: 133-136
99. Roth BJ, Yeap BY, Wilding G, Kasimis B, McLeod D, Loehrer PJ Taxol in advanced, hormone-refractory carcinoma of the prostate.: a phase II trial of the Eastern Cooperative Oncology Group. Cancer 1993; 72.: 2457-2460
100. Einzig AI, Wiernik PH, Lipsitz S, Benson AB III Phase II trial of taxol in patients with adenocarcinoma of the upper gastrointestinal tract (UGIT).: the Eastern Cooperative Oncology Group (ECOG) results. Proc Am Soc Clin Oncol 1993; 12.: 194-194 abstract.
101. Brown T, Tangen C, Fleming T, Macdonald J A phase II trial of taxol and granulocyte colony stimulating factor (G-CSF) in patients with adenocarcinoma of the pancreas. Proc Am Soc Clin Oncol 1993; 13.: 200-200 abstract.
102. Rowinsky EK, Onetto N, Canetta RM, Arbuck SG Taxol.: the first of the taxanes, an important new class of antitumor agents. Semin Oncol 1992; 19.: 646-662
103. Wilson WH, Chabner BA, Bryant G, Phase II study of paclitaxel in relapsed non-Hodgkin's lymphomas. J Clin Oncol 1995; 13.: 381-386
104. Younes A, Sarris A, Melnyk A, Three-hour paclitaxel infusion in patients with refractory and relapsed non-Hodgkin's lymphoma. J Clin Oncol 1995; 13.: 583-587
105. Roth BJ, Dreicer R, Einhorn LH, Paclitaxel in previously untreated, advanced transitional cell carcinoma of the urothelium.: a phase II trial of the Easten Cooperative Oncology Group (ECOG). Proc Am Soc Clin Oncol 1994; 13.: 230-230 abstract.
106. Ajani JA, Ilson DH, Daugherty K, Pazdur R, Lynch PM, Kelsen DP Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J Natl Cancer Inst 1994; 86.: 1086-1091
107. Motzer RJ, Bajorin DF, Schwartz LH, Phase II trial of paclitaxel shows antitumor activity in patients with previously treated germ cell tumors. J Clin Oncol 1994; 12.: 2277-2283
108. Denis J-N, Correa A, Greene AE An improved synthesis of the taxol side chain and of RP 56976. J Org Chem 1990; 55.: 1957-1959
109. Holton RA, Somoza C, Kim H-B, First total synthesis of taxol. 1. Functionalization of the B ring. J Am Chem Soc 1994; 116.: 1597-1598
110. Holton RA, Kim H-B, Somoza C, First total synthesis of taxol. 2. Completion of the C and D rings. J Am Chem Soc 1994; 116.: 1599-1600
111. Nicolaou KC, Yang Z, Liu JJ, Total synthesis of taxol. Nature 1994; 367.: 630-634
112. Ringel I, Horwitz SB Studies with RP 56976 (taxotere).: a semisynthetic analogue of taxol. J Natl Cancer Inst 1991; 83.: 288-291
113. Bissery MC, Guenard D, Gueritte-Voegelein F, Lavelle F Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue. Cancer Res 1991; 51.: 4845-4852
114. Chevallier B, Fumoleau P, Kerbrat P, Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer.: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer. J Clin Oncol 1995; 13.: 314-322
115. Trudeau ME, Eisenhauer E, Lofter W, Phase II study of taxotere as first line chemotherapy for metastatic breast cancer (MBC).: a National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) study. Proc Am Soc Clin Oncol 1993; 12.: 64-64 abstract.
116. Fossella FV, Lee JS, Murphy WK, Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer. J Clin Oncol 1994; 12.: 1238-1244
117. Francis PA, Rigas JR, Kris MG, Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer. J Clin Oncol 1994; 12.: 1232-1237
118. Francis P, Schneider J, Hann L, Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer. J Clin Oncol 1994; 12.: 2301-2308
119. De Forni M, Rougier P, Adenis A, Phase II study of taxotere (RP 56976, docetaxel) in locally advanced and/or metastatic pancreatic cancer. Ann Oncol 1994; 5.: Suppl 5.: 202-202 abstract.